What is Leerink Partnrs’ Estimate for TVTX FY2026 Earnings?

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at Leerink Partnrs increased their FY2026 earnings per share (EPS) estimates for Travere Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of $0.52 per share for the year, up from their prior forecast of $0.51. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.93) per share.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. The company had revenue of $62.90 million for the quarter, compared to analysts’ expectations of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The business’s revenue for the quarter was up 69.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.17) earnings per share.

TVTX has been the topic of a number of other research reports. Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $9.00 to $27.00 in a report on Monday, October 21st. Cantor Fitzgerald started coverage on Travere Therapeutics in a report on Friday, January 10th. They set an “overweight” rating on the stock. Barclays boosted their target price on Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. HC Wainwright boosted their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. Finally, Wedbush boosted their target price on Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Travere Therapeutics Stock Performance

TVTX opened at $19.46 on Tuesday. The business’s 50 day moving average is $18.21 and its 200-day moving average is $14.72. The stock has a market cap of $1.52 billion, a PE ratio of -4.28 and a beta of 0.70. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $20.33.

Insiders Place Their Bets

In other news, CAO Sandra Calvin sold 15,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares in the company, valued at $945,842.94. The trade was a 21.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jula Inrig sold 2,066 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total transaction of $39,460.60. Following the transaction, the insider now owns 59,883 shares in the company, valued at approximately $1,143,765.30. This represents a 3.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,596 shares of company stock worth $527,262. Corporate insiders own 4.06% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC lifted its stake in shares of Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after purchasing an additional 3,065 shares during the last quarter. Quarry LP acquired a new stake in shares of Travere Therapeutics in the 3rd quarter valued at $105,000. Diversified Trust Co acquired a new stake in shares of Travere Therapeutics in the 3rd quarter valued at $161,000. DRW Securities LLC acquired a new stake in shares of Travere Therapeutics in the 2nd quarter valued at $95,000. Finally, Aigen Investment Management LP acquired a new stake in shares of Travere Therapeutics in the 3rd quarter valued at $170,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.